Elsevier, a global leader in scientific publishing and analytics, today officially released its 2025 "Highly Cited Chinese Researchers" list, recognizing the significant contributions of leading scholars in China. For the 12th consecutive year, researchers from BGI Group have been selected, underscoring the organization's long-standing commitment to advancing scientific innovation.
The prestigious list includes Wang Jian, Co-founder and Chairman of the Board of Directors of BGI Group; Yang Huanming, Co-founder, Member of the Board of Directors of BGI Group, and Director-General of BGI; and Xu Xun, Chief Researcher of BGI Group and Director of State Key Laboratory of Genome and Multi-omics Technologies.
The “Highly Cited Chinese Researchers” list is widely regarded as a benchmark of scientific excellence, identifying top scholars whose work demonstrates exceptional research contribution and innovation value across various disciplines. Inclusion on this list recognizes a scholar’s or an institution’s pivotal role in driving advancements at the forefront of their field, particularly through the development and application of transformative technologies.
The 2025 list features 6,310 researchers from 543 universities, enterprises, and research institutions, spanning 83 State Council Academic Degree Committee (SCADC) subjects across 10 SCADC subject areas designated by the China State Council Academic Degree Committee and Ministry of Education. For BGI Group, the consistent recognition of the scientists on such a distinguished list reflects the organization’s sustained contributions to high-quality research, fostering innovation on a global scale, and advancing its mission of “Omics for All”.
This accolade from Elsevier complements BGI Group's continued presence on other prominent global rankings. In November 2025, four BGI researchers were named among Clarivate Analytics’ annual “Highly Cited Researchers,” for the 11th consecutive year.
Further underscoring its scientific impact, BGI secured its tenth consecutive year as the top-ranked biological sciences corporate institution in the Asia-Pacific region and fourth globally in the 2025 Nature Index annual rankings.
As of January 2026, BGI researchers have contributed to an impressive total of 5,961 scientific papers. This extensive body of work includes 886 publications featured in top-tier “CNNS” journals (the leading academic journals Cell, Nature, New England Journal of Medicine, Science, and their related publications, if any), with 188 published in flagship journals.
The consistent inclusion of BGI Group researchers on impactful lists underscores the organization’s sustained scholarly impact. Going forward, BGI Group remains steadfast in its mission, focusing on the foundational research and technological innovation to address complex challenges in genomics and advance their applications to improve human health.